These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

467 related items for PubMed ID: 16387086

  • 1. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients.
    Kovac D, Kotnik V, Kandus A.
    Transplant Proc; 2005 Dec; 37(10):4230-4. PubMed ID: 16387086
    [Abstract] [Full Text] [Related]

  • 2. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):1984-92. PubMed ID: 17161352
    [Abstract] [Full Text] [Related]

  • 3. Results of kidney transplantation in patients receiving MMF- or MMF and basiliximab-containing immunosuppression.
    Tojimbara T, Nakajima I, Sato S, Nakamura M, Kawase T, Kai K, Tsuda S, Kudo S, Fuchinoue S, Teraoka S.
    Transplant Proc; 2004 Sep 20; 36(7):2087-9. PubMed ID: 15518755
    [Abstract] [Full Text] [Related]

  • 4. Cyclosporine-sparing effect of basiliximab in renal transplant recipients with mycophenolate mofetil.
    Tojimbara T, Sato S, Koyama I, Nanmoku K, Sekijima M, Tonsyo M, Kai K, Kato Y, Urashima Y, Nakajima I, Fuchinoue S, Teraoka S.
    Transplant Proc; 2005 Mar 20; 37(2):895-8. PubMed ID: 15848568
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
    Offner G, Toenshoff B, Höcker B, Krauss M, Bulla M, Cochat P, Fehrenbach H, Fischer W, Foulard M, Hoppe B, Hoyer PF, Jungraithmayr TC, Klaus G, Latta K, Leichter H, Mihatsch MJ, Misselwitz J, Montoya C, Müller-Wiefel DE, Neuhaus TJ, Pape L, Querfeld U, Plank C, Schwarke D, Wygoda S, Zimmerhackl LB.
    Transplantation; 2008 Nov 15; 86(9):1241-8. PubMed ID: 19005406
    [Abstract] [Full Text] [Related]

  • 6. Effect of basiliximab on renal allograft rejection within 1 year after transplantation.
    Lee BM, Oh CK, Jin SH, Kim JH, Kim SJ, Kim H, Shin GT.
    Transplant Proc; 2006 Sep 15; 38(7):2025-8. PubMed ID: 16979988
    [Abstract] [Full Text] [Related]

  • 7. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A, Arnol M, Omahen K, Oblak M, Vidan-Jeras B, Kmetec A, Bren AF.
    Transplantation; 2010 Apr 27; 89(8):1022-7. PubMed ID: 20075788
    [Abstract] [Full Text] [Related]

  • 8. Basiliximab induction in renal transplantation: long-term outcome.
    Atlani M, Sharma RK, Gupta A.
    Saudi J Kidney Dis Transpl; 2013 May 27; 24(3):473-9. PubMed ID: 23640617
    [Abstract] [Full Text] [Related]

  • 9. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
    Grego K, Arnol M, Bren AF, Kmetec A, Tomaziĉ J, Kandus A.
    Transplant Proc; 2007 Dec 27; 39(10):3093-7. PubMed ID: 18089329
    [Abstract] [Full Text] [Related]

  • 10. Induction immunosuppressive therapy in renal transplantation: does basiliximab make the difference?
    Jorge S, Guerra J, Silva S, Santana A, Mil-Homens C, Prata MM.
    Transplant Proc; 2008 Apr 27; 40(3):693-6. PubMed ID: 18454989
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
    Ulsh PJ, Yang HC, Holman MJ, Ahsan N.
    J Transpl Coord; 1999 Jun 27; 9(2):114-8. PubMed ID: 10703393
    [Abstract] [Full Text] [Related]

  • 14. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Transplantation; 2001 Apr 27; 71(8):1091-7. PubMed ID: 11374408
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Results of renal transplantation with different immunosuppressive regimens.
    Folkmane I, Bicans J, Chapenko S, Murovska M, Rosentals R.
    Transplant Proc; 2002 Mar 27; 34(2):558-9. PubMed ID: 12009623
    [No Abstract] [Full Text] [Related]

  • 17. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.
    Ojogho O, Sahney S, Cutler D, Baron PW, Abdelhalim FM, James S, Zuppan C, Franco E, Concepcion W.
    Pediatr Transplant; 2005 Feb 27; 9(1):80-3. PubMed ID: 15667617
    [Abstract] [Full Text] [Related]

  • 18. Effective immunoprophylaxis with basiliximab plus triple therapy in renal transplantation: five-year single-center experience.
    Kandus A, Grego K, Arnol M, Kovac D, Lindic J, Buturović J, Ponikvar R, Bren AF.
    Transplant Proc; 2006 Nov 27; 38(9):2853-5. PubMed ID: 17112847
    [Abstract] [Full Text] [Related]

  • 19. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
    Budde K, Bosmans JL, Sennesael J, Zeier M, Pisarski P, Schütz M, Fischer W, Neumayer HH, Glander P.
    Clin Nephrol; 2007 Mar 27; 67(3):164-75. PubMed ID: 17390741
    [Abstract] [Full Text] [Related]

  • 20. Recovery of graft function in pediatric kidney transplantation is not affected by delayed introduction of cyclosporine.
    Cransberg K, Bouts AH, Cornelissen EA, Lilien MR, Van Hoeck KJ, Hop WC, Nauta J.
    Transplantation; 2008 Nov 15; 86(9):1199-205. PubMed ID: 19005400
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.